Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001044823 | SCV001208643 | benign | not provided | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004031373 | SCV004911000 | uncertain significance | Inborn genetic diseases | 2024-01-23 | criteria provided, single submitter | clinical testing | The c.2653G>A (p.E885K) alteration is located in exon 16 (coding exon 16) of the ARHGEF18 gene. This alteration results from a G to A substitution at nucleotide position 2653, causing the glutamic acid (E) at amino acid position 885 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV001044823 | SCV005313060 | benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003928676 | SCV004738927 | likely benign | ARHGEF18-related disorder | 2019-04-09 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |